DiaMedica Therapeutics
NASDAQ: DMACMinneapolis, US · Canada (Federal Level) corporation · 2 known investors
DiaMedica Therapeutics develops therapies aimed at reducing ischemia in patients with serious vascular diseases, with an initial focus on preeclampsia, fetal growth restriction, and acute ischemic stroke. It is a clinical-stage biopharmaceutical company working on treatments for ischemic disorders.
Founders & leadership
DJ
David J. WambekeExecutive
LM
Lorianne MasuokaExecutive
RP
Rick PaulsExecutive
SK
Scott KellenExecutive
TV
Todd VerdoornExecutive
PP
Paul PapiNamed on SEC filing
Z(
Zhenyu (Jerry) XiaoNamed on SEC filing
DG
David GurveyNamed on SEC filing
Board
CP
Charles P. SembaBoard director
RK
RM
R. Michael GiuffreBoard director
TN
Tanya N. LewisBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$110.4M disclosed across 6 rounds · 2018–2025
▶$30.1MraisedJul 2025 · 14 investors · BiotechnologyRule 506(b)
▶$30.1MraisedJul 2025 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David J. WambekeExecutive Officer
- Charles P. SembaDirector
- Lorianne MasuokaExecutive Officer
- Daniel O'ConnorDirector
- Scott KellenExecutive Officer
- Richard KuntzDirector
- Michael R. GiuffreDirector
- Tanya N. LewisDirector
- Rick PaulsExecutive Officer, Director
- James T. ParsonsDirector
- Offering amount
- $30.1M
- Amount sold
- $30.1M
- First sale
- Jul 2025
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$11.8MraisedJul 2024 · 10 investors · BiotechnologyRule 506(b)
▶$11.8MraisedJul 2024 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David J. WambekeExecutive Officer
- Charles P. SembaDirector
- Richard KuntzDirector
- R. Michael GiuffreDirector
- Lorianne MasuokaExecutive Officer
- Tanya N. LewisDirector
- Rick PaulsExecutive Officer, Director
- Scott KellenExecutive Officer
- Richard D. PilnikDirector
- James T. ParsonsDirector
- Offering amount
- $11.8M
- Amount sold
- $11.8M
- First sale
- Jun 2024
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$37.5MraisedJun 2023 · 34 investors · BiotechnologyRule 506(b)
▶$37.5MraisedJun 2023 · 34 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dominic CundariExecutive Officer
- Scott KellenExecutive Officer
- David J. WambekeExecutive Officer
- R. Michael GiuffreDirector
- Rick PaulsExecutive Officer, Director
- Richard D. PilnikDirector
- Tanya N. LewisDirector
- Julie DavesExecutive Officer
- Kirsten GruisExecutive Officer
- James T. ParsonsDirector
- Richard KuntzDirector
- Charles P. SembaDirector
- Offering amount
- $37.5M
- Amount sold
- $37.5M
- Sales commissions
- $845.8K
- Placement agents
- Craig-Hallum Capital Group LLC
- First sale
- Jun 2023
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$750KraisedApr 2023 · 1 investors · BiotechnologyRule 506(b)
▶$750KraisedApr 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Julie DavesExecutive Officer
- Tanya N. LewisDirector
- Scott KellenExecutive Officer
- Rick PaulsExecutive Officer, Director
- Kirsten GruisExecutive Officer
- Charles P. SembaDirector
- Dominic CundariExecutive Officer
- Richard D. PilnikDirector
- James T. ParsonsDirector
- R. Michael GiuffreDirector
- Offering amount
- $750K
- Amount sold
- $750K
- First sale
- Apr 2023
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$30MraisedOct 2021 · 10 investors · BiotechnologyRule 506(b)
▶$30MraisedOct 2021 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- R. Michael GiuffreDirector
- Amy L. BurroughsDirector
- Harry W. Alcorn Jr.Executive Officer
- Richard D. PilnikDirector
- Charles P. SembaDirector
- Scott KellenExecutive Officer
- Rick PaulsExecutive Officer, Director
- Sydney GilmanExecutive Officer
- James T. ParsonsDirector
- Offering amount
- $30M
- Amount sold
- $30M
- First sale
- Sep 2021
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$200.9KraisedApr 2018 · 7 investors · BiotechnologyRule 506(b)
▶$200.9KraisedApr 2018 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rick PaulsExecutive Officer, Director
- James ParsonsDirector
- Scott KellenExecutive Officer
- Paul PapiExecutive Officer
- Zhenyu (Jerry) XiaoDirector
- Todd VerdoornExecutive Officer
- Richard PilnikDirector
- David GurveyExecutive Officer
- Michael GiuffreDirector
- Offering amount
- $344.3K
- Amount sold
- $200.9K
- First sale
- Mar 2018
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with DiaMedica Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does DiaMedica Therapeutics do?
- DiaMedica Therapeutics develops therapies aimed at reducing ischemia in patients with serious vascular diseases, with an initial focus on preeclampsia, fetal growth restriction, and acute ischemic stroke. It is a clinical-stage biopharmaceutical company working on treatments for ischemic disorders.
- Who are DiaMedica Therapeutics's investors?
- DiaMedica Therapeutics's investors include CentreStone Ventures, Shepherd Ventures.
- How much funding has DiaMedica Therapeutics raised?
- DiaMedica Therapeutics has disclosed $110.4M raised across 6 rounds.
- Where is DiaMedica Therapeutics headquartered?
- DiaMedica Therapeutics is headquartered in Minneapolis, US.